Heart Failure
Feature
Death of pig heart transplant patient is more a beginning than an end
The landmark case will have much to teach; still, it “turns back the clock” to a time when immunosuppression was especially intense “because we...
Conference Coverage
Real-world data support safety of newer LAA device
More than 18 months after approval, the Watchman FLX left atrial appendage closure device is performing well at 45 days in real-world use.
From the Journals
Silver lining emerges for embolic protection in post-TAVR stroke
A database study found that embolic protection during transcatheter aortic valve replacement may improve outcomes, although not the occurrence, of...
From the Journals
Fewer than half with severe aortic stenosis get new valves
The findings are surprising given the availability of transcatheter options and should sound the alarm for change, experts suggest.
From the Journals
Boosting daily exercise after age 70 tied to lower CVD risk
Exercise ‘trajectories’ after age 65 reveal that those who remain active over time have a lower risk for CVD and death.
Conference Coverage
Finerenone + SGLT2 inhibitor of benefit in diabetes with CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors...
Conference Coverage
‘Striking’ differences in BP when wrong cuff size is used
A new trial bolsters the case for avoiding a one-cuff-size-fits-all approach to measuring blood pressure and for improving patient access to a...
From the Journals
New data explore risk of magnetic interference with implantable devices
Portable electronics embedded with magnets powerful enough to impair CV device functions are proliferating.
From the Journals
AHA targets ‘low-value’ heart care in new scientific statement
Low-value cardiovascular care providing little or no benefit is common, potentially harmful, and costly, and it will take key stakeholders to...
News
FDA okays empagliflozin for HF regardless of ejection fraction
The expanded indication for the SGLT2 inhibitor empagliflozin (Jardiance) now includes heart failure with mid-range or preserved left ventricular...
News
Biden’s FDA chief nominee narrowly wins Senate confirmation
Dr. Robert Califf returns to lead the FDA as the U.S. continues to cope with the pandemic and opioid epidemic.